A citation-based method for searching scientific literature

Lars Edvinsson, Kristian Agmund Haanes, Karin Warfvinge, Diana N Krause. Nat Rev Neurol 2018
Times Cited: 357







List of co-cited articles
867 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Dean Leonardi, Daniel Mikol, Robert Lenz. Lancet Neurol 2017
343
19

Pathophysiology of Migraine: A Disorder of Sensory Processing.
Peter J Goadsby, Philip R Holland, Margarida Martins-Oliveira, Jan Hoffmann, Christoph Schankin, Simon Akerman. Physiol Rev 2017
667
17


Calcitonin gene-related peptide: physiology and pathophysiology.
F A Russell, R King, S-J Smillie, X Kodji, S D Brain. Physiol Rev 2014
515
16

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
Jes Olesen, Hans-Christoph Diener, Ingo W Husstedt, Peter J Goadsby, David Hall, Ulrich Meier, Stephane Pollentier, Lynna M Lesko. N Engl J Med 2004
868
15

Fremanezumab for the Preventive Treatment of Chronic Migraine.
Stephen D Silberstein, David W Dodick, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi. N Engl J Med 2017
320
15

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
Holland C Detke, Peter J Goadsby, Shufang Wang, Deborah I Friedman, Katherine J Selzler, Sheena K Aurora. Neurology 2018
204
15

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Richard B Lipton, David W Dodick, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Armin Szegedi, Joel M Trugman. JAMA 2019
105
14

Ubrogepant for the Treatment of Migraine.
David W Dodick, Richard B Lipton, Jessica Ailani, Kaifeng Lu, Michelle Finnegan, Joel M Trugman, Armin Szegedi. N Engl J Med 2019
126
14

A Controlled Trial of Erenumab for Episodic Migraine.
Peter J Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Feng Zhang, Sandhya Sapra, Hernan Picard, Daniel D Mikol, Robert A Lenz. N Engl J Med 2017
388
14

Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.
Debbie L Hay, Michael L Garelja, David R Poyner, Christopher S Walker. Br J Pharmacol 2018
177
13

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Simona Sacco, Lars Bendtsen, Messoud Ashina, Uwe Reuter, Gisela Terwindt, Dimos-Dimitrios Mitsikostas, Paolo Martelletti. J Headache Pain 2019
164
12

CGRP may play a causative role in migraine.
L H Lassen, P A Haderslev, V B Jacobsen, H K Iversen, B Sperling, J Olesen. Cephalalgia 2002
636
12


Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
Licheng Shi, Sonya G Lehto, Dawn X D Zhu, Hong Sun, Jianhua Zhang, Brian P Smith, David C Immke, Kenneth D Wild, Cen Xu. J Pharmacol Exp Ther 2016
135
11

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
David W Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lanteri-Minet, Vera Osipova, Kerry Palmer, Hernan Picard, Daniel D Mikol, Robert A Lenz. Cephalalgia 2018
241
11

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Wim M Mulleners, Byung-Kun Kim, Miguel J A Láinez, Michel Lanteri-Minet, Patricia Pozo-Rosich, Shufang Wang, Antje Tockhorn-Heidenreich, Sheena K Aurora, Russell M Nichols, Laura Yunes-Medina,[...]. Lancet Neurol 2020
61
18

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Michel D Ferrari, Hans Christoph Diener, Xiaoping Ning, Maja Galic, Joshua M Cohen, Ronghua Yang, Matthias Mueller, Andrew H Ahn, Yael Carmeli Schwartz, Melissa Grozinski-Wolff,[...]. Lancet 2019
129
11

Human models of migraine - short-term pain for long-term gain.
Messoud Ashina, Jakob Møller Hansen, Bára Oladóttir Á Dunga, Jes Olesen. Nat Rev Neurol 2017
91
10

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion.
S Eftekhari, C A Salvatore, A Calamari, S A Kane, J Tajti, L Edvinsson. Neuroscience 2010
210
10

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
Richard B Lipton, Robert Croop, Elyse G Stock, David A Stock, Beth A Morris, Marianne Frost, Gene M Dubowchik, Charles M Conway, Vladimir Coric, Peter J Goadsby. N Engl J Med 2019
120
10



Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats.
Kirk W Johnson, S Michelle Morin, Victor J Wroblewski, Michael P Johnson. Cephalalgia 2019
37
27

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura.
Jakob Møller Hansen, Anne Werner Hauge, Jes Olesen, Messoud Ashina. Cephalalgia 2010
262
10


Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
Richard B Lipton, Peter J Goadsby, Jeff Smith, Barbara A Schaeffler, David M Biondi, Joe Hirman, Susan Pederson, Brent Allan, Roger Cady. Neurology 2020
111
10

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Eva Cernuda-Morollón, Davinia Larrosa, César Ramón, Juan Vega, Pablo Martínez-Camblor, Julio Pascual. Neurology 2013
215
9


CGRP and the Trigeminal System in Migraine.
Smriti Iyengar, Kirk W Johnson, Michael H Ossipov, Sheena K Aurora. Headache 2019
101
9

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
Ronald Marcus, Peter J Goadsby, David Dodick, David Stock, George Manos, Tanya Z Fischer. Cephalalgia 2014
171
9

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock, Vladimir Coric, Richard B Lipton. Lancet 2019
115
9

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
Tiffini Voss, Richard B Lipton, David W Dodick, Nicole Dupre, Joy Yang Ge, Robert Bachman, Christopher Assaid, Sheena K Aurora, David Michelson. Cephalalgia 2016
152
9

A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.
Christopher S Walker, Sajedeh Eftekhari, Rebekah L Bower, Andrea Wilderman, Paul A Insel, Lars Edvinsson, Henry J Waldvogel, Muhammad A Jamaluddin, Andrew F Russo, Debbie L Hay. Ann Clin Transl Neurol 2015
114
9



Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
David W Dodick, Stephen D Silberstein, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi. JAMA 2018
204
9

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati,[...]. J Headache Pain 2021
31
29

Origin of pain in migraine: evidence for peripheral sensitisation.
Jes Olesen, Rami Burstein, Messoud Ashina, Peer Tfelt-Hansen. Lancet Neurol 2009
348
8


Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
Tony W Ho, Kathryn M Connor, Ying Zhang, Eric Pearlman, Janelle Koppenhaver, Xiaoyin Fan, Christopher Lines, Lars Edvinsson, Peter J Goadsby, David Michelson. Neurology 2014
160
8

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.
David J Hewitt, Sheena K Aurora, David W Dodick, Peter J Goadsby, Yang Joy Ge, Robert Bachman, Donna Taraborelli, Xiaoyin Fan, Christopher Assaid, Christopher Lines,[...]. Cephalalgia 2011
196
8

Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
Agustin Melo-Carrillo, Andrew M Strassman, Rony-Reuven Nir, Aaron J Schain, Rodrigo Noseda, Jennifer Stratton, Rami Burstein. J Neurosci 2017
86
9

Calcitonin gene-related peptide (CGRP): a new target for migraine.
Andrew F Russo. Annu Rev Pharmacol Toxicol 2015
183
8

Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier.
Rodrigo Noseda, Aaron J Schain, Agustin Melo-Carrillo, Jason Tien, Jennifer Stratton, Fanny Mai, Andrew M Strassman, Rami Burstein. Cephalalgia 2020
33
24





Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.